Gary Johnson, MD
Urology · Salt Lake City, UTNPI 1144223827
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2024 at $5,123 and has fallen 88.3% since, to $598 in 2025.
Across 202 payments — averaging $72.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Boston Scientific$1K
- Astellas Pharma US Inc$364
- AbbVie$327
- Endo Pharmaceuticals Inc.$229
- Urogen Pharma, Inc.$179
- plus $2K from 31 others
What the payments were for
- Travel & lodging$2,01914%
- Food & beverage$4,55331%
- Education$8,00555%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $10,575 |
| Boston Scientific | 60 | $1,144 |
| Astellas Pharma US Inc | 21 | $364 |
| AbbVie(2 entities) | 13 | $327 |
| Endo Pharmaceuticals Inc. | 16 | $229 |
| Urogen Pharma, Inc. | 3 | $179 |
| Ferring Pharmaceuticals Inc. | 3 | $166 |
| Johnson & Johnson(2 entities) | 8 | $129 |
| Bayer | 6 | $126 |
| Procept Biorobotics Corporation | 1 | $120 |
| Amgen | 2 | $99 |
| Cook Medical LLC | 1 | $98 |
| Medtronic | 1 | $92 |
| Travere Therapeutics, Inc. | 5 | $83 |
| Myriad Genetic Laboratories, Inc. | 5 | $82 |
| Antares Pharma, Inc. | 6 | $80 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Novartis | 3 | $54 |
| Progenics Pharmaceuticals, Inc. | 2 | $54 |
| Laborie Medical Technologies Corp. | 3 | $52 |
| Dendreon Pharmaceuticals LLC | 2 | $43 |
| Pfizer | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Quidel Corporation | 1 | $41 |
| Merck | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| Axonics, Inc. | 2 | $27 |
| Civco Medical Instruments | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Healthtronics Stone Solutions, LLC | 1 | $18 |
| Photocure Inc | 1 | $17 |
| Profound Medical Corp. | 1 | $16 |
| Urovant Sciences Inc | 1 | $16 |
| Neotract Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,324
- JELMYTO$142
- ADSTILADRIN$122
- Lupron Depot$121
- AquaBeam Robotic System$120
How this compares
$14,577 in reported general payments places this provider in the 80th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 31 | $25,380 |
| GemtesaVibegron | 28 | $17,259 |
| Tamsulosin Hcl | 185 | $2,115 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $1,767 |
| Dutasteride | 42 | $1,549 |
| Doxycycline Monohydrate | 30 | $678 |
| Finasteride | 36 | $462 |
| Solifenacin Succinate | 15 | $336 |
| Doxycycline Hyclate | 15 | $288 |
| Ketorolac Tromethamine | 32 | $285 |
| Ciprofloxacin Hcl | 32 | $243 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $364 | $25,38031 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $17,25928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 urology providers in Utah.
Other urology in Salt Lake City
- William BrantSalt Lake City$290K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Stephen SummersSalt Lake City$15K
- Jeremy MyersSalt Lake City$15K
- Sara LenherrSalt Lake City$12K
- Mitchell BassettSalt Lake City$10K
- Joseph ArmstrongSalt Lake City$9K
- Steven LynchSalt Lake City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.